InvestorsHub Logo
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

Re: Oren1976 post# 963

Saturday, 05/20/2017 7:22:23 PM

Saturday, May 20, 2017 7:22:23 PM

Post# of 2099
Oren, I leave the pricing to the market. On one hand, companies spend millions/billions to research and get a drug to market. They're not going to do it if the risk/reward is not there.

Just look at VB-201. They spent millions researching it but it failed in psoriasis. VBL (and its investors) is getting nothing (so far) back for the millions it spent. Numerous other examples of drug companies not getting a return on their investments because the drug failed. So when a drug does make it to market, I do understand the rational for some of the pricing. The price factors in such things as profits, funding for future research and failed investments ... not to mention other SG&A expenses.

What Shkreli did, though, was unethical.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News